Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study is testing an oral drug called TQ05105 for adults with a serious complication called chronic graft-versus-host disease (cGVHD) that has not responded well to standard steroid treatment. The trial aims to find a safe and effective dose and see if the drug can help contr…

This study is testing whether adding a new tablet called TQ-A3334 to standard hepatitis B medications works better than the standard medications alone. It involves 116 adults with chronic hepatitis B who are either starting treatment or already on stable treatment. The main goal …

This study is testing whether a new oral drug called TQ05105 is better than the standard drug hydroxyurea at controlling moderate to high-risk myelofibrosis, a serious bone marrow disorder. It involved 107 patients who were randomly assigned to receive one of the two treatments. …

This large Phase 3 trial is comparing two different drug combinations as first treatment for advanced colorectal cancer that has spread and has specific genetic markers (RAS/BRAF wild-type). 748 participants will receive either the experimental combination (anlotinib plus chemoth…

This study is testing whether TQB3454 tablets can help people with advanced bile duct cancer that has a specific genetic change (IDH1 mutation) and has stopped responding to standard chemotherapy. About 165 participants are randomly assigned to receive either the experimental pil…

This large, late-stage trial is testing whether adding a new oral drug called TQB3616 to a standard hormone therapy (fulvestrant) works better for controlling advanced breast cancer. It involves 432 postmenopausal women with a specific type of breast cancer (HR-positive, HER2-neg…